Title: Antiphospholipid Syndrome In Pregnancy
Authors: Dr Arati Nayak, Dr Arata Kumar Swain, Dr Pradipta Kumar Patel, Dr Harekrusna Dalai
DOI: http://dx.doi.org/10.18535/jmscr/v4i1.08
The antiphospholipid syndrome (APS) is a multisystemic disease, characterized by venous or arterial thromboses, or certain obstetric complications, and the presence of antiphospholipid antibodies (APAs) (1-4). Lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-beta 2 glycoprotein 1 (anti-β2GP1) antibodies are the main antibodies in this syndrome (1;2;) APS occurs in isolation as a primary APS in more than 50% of the cases, but can be associated with other autoimmune diseases, most often with systemic lupus erythemathosus (SLE). Twenty to 35% of women with SLE develop APS (6). APS occurs for the most part in young women of fertile age (7). The most characteristic feature of obstetrical APS is miscarriage, It occurs rarely in children, and only 12% of all APS occur after 50 years of age(8)
1. de LB, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodiesfrom clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008 Apr;4(4):192-9. 2. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis,management, and controversies. Obstet Gynecol 2003 Jun;101(6):1333-44. 3. Ahmed K, Darakhshan A, Au E, Khamashta MA, Katsoulis IE. Postpartum spontaneous colonic perforation due to antiphospholipid syndrome. World J Gastroenterol 2009 Jan 28;15(4):502-5. 4. Carp HJ. Antiphospholipid syndrome in pregnancy. Curr Opin Obstet Gynecol 2004 Apr;16(2):129-35. 5. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet & Gynecol 2010 Dec;116(6):1433-43. 6. Tincani A, Andreoli L, Chighizola C, Meroni PL. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity 2009 May;42(4):257-9 7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 Feb;4(2):295-306.) 8. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010;340:c2541. 9. Cervera R, Piette J C, Font J, Khamashta M A, Shoenfeld Y, Camps M T. et al Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002 461019–1027.1027 [PubMed] 10. Cervera R, Balasch J. The management of pregnant patients with antiphospholipid syndrome. Lupus200413683–687.687 [PubMed] 11. Branch D W, Khamashta M A. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 20031011333–1344.1344 [PubMed] 12. Carmona F, Balasch J. Fetal and obstetric manifestations and infertility in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette, Shoenfeld Y, eds. The antiphospholipide syndrome II: autoimmune thrombosis Amsterdam: Elsevier, 2000205–211.211 Asherson R A. The catastrophic antiphospholipid syndrome. J Rheumatol 199219508–512.512 [PubMed] 13. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 Feb;4(2):295-306 14. Si-Hoe CK, Thng CH, Chee SG, Teo EK, Chng HH. Abdominal computed tomo-graphy in systemic lupus erythematosus. Clin Radiol 1997 Apr;52(4):284-9. 15. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005 Oct;20(2):105-1218] Raval M, Paul A. Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia. Case Rep Neurol 2010;2(3):150-6 16. Csepany T, Bereczki D, Kollar J, Sikula J, Kiss E, Csiba L. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol 2003 Nov; 250(11):1348-54.. 17. Ringrose DK. Anaesthesia and antiphospholipid syndrome – a review of 20 patients. Int J Obstet Anaesth 1997;6: 107–111. 18. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–763. 19. Julkunen H. Pregnancy in systemic lupus erythematosus. Contraception, fetal outcome and congenitalheart block. Acta Obst Gynecol Scand 1994;73:517–520. 20. MacLean M, Cumming G, McCall F, Walker I, Walker J. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994;101:103–106. 21. Silver RM, Branch DW. Recurrent miscarriage: autoimmune considerations. Clin Obstet Gynaecol1994;37:745–760. 22. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301–3304.,. 23. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin in a general obstetric population. Am J Obstet Gynecol 1989;161:369–373. 24. Perez MC, Wilson WA, Brown HL, Scopelitis E. Anti-cardiolipin antibodies in unselected pregnant women in relationship to fetal outcome. J Perinatol 1991;11:33–36 25. Branch DW, Scott JR, Kochenour NK. Obstetric complications associated with lupus anticoagulant.N Engl J Med 1985;313:1322–1326. 26. Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisolone suppression of maternal lupus anticoa-gulant. Lancet 1983;i:1361–1363., 27. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetalloss and thrombocytopenia. Predictive value of the anticardiolpin antibody test. Arch Intern Med1986;146:2153–2156. 28. Reece EA, Garofalo J, Zheng XZ, Assimakopoulos E. Pregnancy outcome – influence of antiphospholipid antibody titer, prior pregnancy loss and treatment. J Reprod Med 1997;42:49–55., 29. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994;120:470–475.. 30. Katano K, Aoki K, Ogasawara M, et al. Specific ntiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Lupus 1995;4:304–308., 31. Buchanan NMM, Khamashta MA, Morton KE, Kerslake S, Baguley E, Hughes GRV. A study of 100 high risk lupus pregnancies. Am J Rep Immunol 1992;28:192–194. 32. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger JTA. Pregnancy outcome inwomen with systemic lupus erythematosus treated with immune-suppressive drugs. J Rheumatol 1993;20:1152–1157.. 33. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe pre-eclampsia. Obstet Gynecol 1988;73:541–545. 34. Moodley J, Bhoola V, Duursma J, Pudifin D, Byrne S, Kenoyer DG. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. South African Med J 1995;85:105–107. 35. Yasuda M, Takakuwa K, Tanaka K. Studies on the association between the anticardiolipin antibody and pre-eclampsia. Acta Med Biol 1994;42:145–149. 36. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe earlyonset preeclampsia. Am J Obstet Gynecol 1995;173:1042–1048 37. Birdsall MA, Pattison NS, Chamley L. Antiphospholipid antibodies in pregnancy. Aust N Z J Obstet Gynecol 1992;32:328–330., and premature delivery [29, 30] 47. Kelly T, Whittle MJ, Smith DJ, Ryan G. Lupus anticoagulant and pregnancy. J Obstet Gynecol1996;16:26–31. 38. Botet F, Romera G, Montagut P, Carmona F, Balasch J. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinat Med 1997;25:192–196.. 39. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphos-pholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614–620., 40. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997;6:509–513. 41. Backos M, Rai R, Baxter N, Chilcott I T, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999;106:102–107.. 42. Cowchock FS. Autoantibodies and pregnancy loss. N Engl J Med 1997;337:197–198.. 43. Empsom M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody:a systematic review of therapeutic trials. Obstet Gynecol 2002;99:135–144.. 44. Silver R, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisolone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody positiveobstetric patients. Am J Obstet Gynecol 1993;169:1411–1417. 45. Balasch J, Carmona F, Lopez-Soto A, et al owchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol 1997;176:1099–1100.. 46. Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trialusing low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet Gynecol 2003;22:233–239. 47. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisolone with low dose heparin treatment. Am J Obstet Gynecol 1992;166:1318–1323.. 48. Ruffati A, Orsini A, Di Lenardo L, et al 49. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss–treatment withheparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584–1589. 50. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (orantiphos-pholipid ntibodies). Br Med J 1997; 314:253–257., although not all studies have shown a benefit in this subgroup 51. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized,controlled trial of treatment. Obstet Gynecol 2002;100:408–413. 52. de Swiet M, Ward PD, Fidler J, et al. Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 1983;90:1129–1134. 53. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancyand the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J ObstetGynecol 1993;168:1265–1270. 54. Nelson-Piercy C, Letsky E, de Swiet M. Low molecular weight heparin for obstetric thromboprophylaxis: experience of 69 pregnancies in 61 high risk women. Am J Obstet Gynecol1997;176:1062–1068.. 55. Smith R, Stevenson JC, Winearls CG, Woods CG, Wordsworth BP. Osteoporosis of pregnancy. Lancet 1985;1:1178–1180. 56. Khastgir G, Studd J. Pregnancy-associated osteoporosis. Br J Obstet Gynaecol 1994;101:836–838. 57. Smith R, Athanasou NA, Ostlere SJ, Vipond SE. Pregnancy-associated osteoporosis. QJM 1995;88:865–878.. 58. Nelson-Piercy C. Heparin-induced osteoporosis in pregnancy. Lupus 1997;6:500–504. 59. Greer IA, Nelson-Piercy C. Systematic review of safety and efficacy of LMWH in pregnancy. Br J Obstet Gynaecol 2004. In press.. Although Factor Xa levels may be used to monitor LMWH [67] 67. Hunt BJ, Doughty H, Majumdar G, et al. 60. Hunt BJ, Khamashta MA, Lakasing L, Williams F, Nelson-Piercy C, Hughes GRV. Thromboprophylaxis in antiphos-pholipid syndrome pregnancies with previous cerebral arterialthrombotic events: is warfarin preferable? Thromb Haemost 1998;79:1060–1061.. 61. Nelson-Piercy C. Low molecular weight heparin for obstetric thromboprophylaxis. Br J Obstet Gynaecol 1994;101:6–8.. 62. Shaul WL, Hall JG. Multiple congenital anomalies associated with oral anticoagulants. Am J Obstet Gynecol 1977;127:191–198.. 63. Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197–203., 64. Vitale N, Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999;33:1637–1641. 65. Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002;99:35–40.. 66. Kwak JYH, Barini R, Gilman-Sachs A, Beaman KD, Beer AE. Down-regulation of maternalantiphospholipid antibodies during early pregnancy and pregnancy outcome. Am J Obstet Gynecol 1994; 171:239–246. 67. Laskin CA, Bombardier C, Hannah ME, et al. Prednisolone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337:148–153.. 68. Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995;172:690–694. 69. Kaaja R, Julkunen H, Ammala P, Palouso T, Kurki P. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated ithntiphospholipid antibodies.Acta Obstet Gynaecol Scand 1993;72:63–66. 70. Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Van Assche A, Vermylen J. High-dose intravenous immunoglobulin in a pregnant patient with antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost 1994;71:741–747 71. Fishman P, Falach Vaknine E, Zigelman R, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest1993;21:1834–1837. 72. Gordon C, Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus 1998;7:429–433. 73. Triolo G, Ferrante A, Ciccia F, et al.
Abstract
References
